Vaginal Dryness Treatment: The Safe, Effective Option Most Women Are Never Offered

Vaginal dryness treatment

. . . is something millions of women desperately need — and almost never receive.

A study of more than 1.8 million women on Medicare, all of whom had a documented diagnosis of genitourinary syndrome of menopause (the medical term for vaginal and urinary symptoms caused by estrogen loss), found that only 9% filled a prescription for vaginal estrogen.

9%. Despite the fact that vaginal estradiol is safe, effective, minimally absorbed, and — for many women — dramatically life-changing.

I've heard from women who stopped having sex because the pain became unbearable. Women whose marriages were suffering. Women told by their doctors that vaginal dryness, recurrent UTIs, and urinary urgency were simply "what happens at your age." Women who didn't know there was any option at all.

There is. It's called vaginal estradiol, and it's one of the most underused, underoffered treatments in women's health.

I'm Steve Goldring, a pharmacist with over 25 years of clinical experience and the past decade spent focused exclusively on hormone education. In this post I want to explain what vaginal estradiol is, why it works, why so few women are offered it, and what to do if your own doctor is one of the ones not offering it.

What Is Genitourinary Syndrome of Menopause?

Most women know that menopause brings hot flashes and night sweats. Far fewer know about the other set of symptoms — the ones that don't get better on their own, the ones nobody talks about, and the ones that can quietly devastate quality of life for years or decades.

These symptoms fall under a clinical umbrella called genitourinary syndrome of menopause, or GSM. They include:

• Vaginal dryness and vaginal itching
• Painful sexual intercourse (dyspareunia)
• Recurrent urinary tract infections
• Urinary urgency and urinary incontinence

Research shows that GSM affects somewhere between 27% and 84% of postmenopausal women. That's an enormous range, but even the low end means roughly one in four women. The high end means the majority.

And unlike hot flashes, which often improve over time, GSM gets worse the longer you're in menopause. Multiple studies confirm this progression. A systematic review in the journal Climacteric found that GSM symptoms increase in both frequency and severity with time since menopause. A study in the journal Menopause emphasized that these symptoms are unlikely to improve without treatment.

The longer a woman goes without estradiol, the more the vaginal tissues atrophy. The dryness deepens. The pain worsens. This isn't a nuisance that resolves on its own — it's a progressive condition that requires treatment.

Why Only 9% of Women Get the Vaginal Dryness Treatment That Works

If vaginal estradiol is safe and effective, why are 91% of women with a GSM diagnosis going without it? In my view, there are two reasons.

Reason 1: The Fear Factor

Even when women do receive a prescription for vaginal estradiol, many never fill it. The fear is real, and it doesn't come from nowhere. It comes directly from the FDA's black box warning — a set of alarming paragraphs required on every estrogen product for the past two decades, warning of cardiovascular disease, breast cancer, and probable dementia.

Those warnings were terrifying. They were also based on research that had nothing to do with vaginal estrogen. The Women's Health Initiative study that generated those warnings used oral conjugated equine estrogens — not vaginal estradiol — and didn't study low-dose vaginal applications at all. Yet the FDA applied the same black box to vaginal products as to systemic ones.

The result: women saw language about breast cancer and dementia on their vaginal estradiol prescription and threw it in the trash. Or never filled it.

The good news: as of November 2025, the FDA removed those warnings. The FDA formally announced the removal of cardiovascular disease, breast cancer, and probable dementia language from the boxed warnings on all menopausal hormone therapy products, including vaginal estrogen. The "use lowest effective dose for shortest duration" language was removed as well.

For a deeper look at what the black box warning said and why those claims were misleading, see my post on the FDA's black box warning.

The fear is understandable. The science never supported it — and now, at least officially, the FDA has caught up.

Reason 2: The Ignorance Factor

The second reason is harder to say but important to name: many doctors simply don't bring it up. Not because they're uncaring, but because they weren't trained on it. Doctors receive only a few hours of menopause and hormone education across their entire medical school and residency training. Vaginal estradiol isn't on most providers' radar.

I've heard from women who have been on systemic HRT for a year — patches, pills, progesterone — without anyone ever mentioning that a separate vaginal product exists for GSM. Women who told their doctor about painful sex or recurrent UTIs and were offered nothing. Women who asked whether something hormonal might be going on and were told "that's just what happens at your age."

That response is not acceptable. Vaginal dryness treatment exists, it works, and it should be offered.

What Vaginal Estradiol Actually Is

Vaginal estradiol is estradiol — the same bioidentical hormone your ovaries produced before menopause — applied locally to the vaginal tissues rather than taken systemically.

Because it's applied locally, it's minimally absorbed into the bloodstream. Studies show that low-dose vaginal estradiol products keep serum estradiol levels well within the postmenopausal range. This matters enormously for women who are concerned about systemic hormone exposure — vaginal estradiol delivers results where they're needed without meaningfully raising overall estradiol levels.

It's available in several forms, all FDA-approved:

• Vaginal creams — applied directly to vaginal tissues
• Vaginal tablets or suppositories — inserted vaginally
• Vaginal ring — a silicone ring embedded with estradiol, inserted into the vaginal cavity and replaced every 90 days
• Compounded preparations — troches, suppositories, or other forms prepared by a compounding pharmacy

One important note: some women experience burning, itching, or irritation with vaginal estradiol products. In almost every case, this is caused by the cream base or inactive ingredients — not the estradiol itself. A knowledgeable provider or skilled compounding pharmacist can work around this. If you've tried one form and had a reaction, that doesn't mean vaginal estradiol isn't an option for you — it means you likely need a different formulation.

Vaginal estradiol also does not require added progesterone to protect the uterine lining. Because systemic absorption is so low, the uterine lining is not stimulated the way it would be by systemic estrogen. This is a meaningful practical difference for many women.

What Vaginal Estradiol Treats

Clinical trials and systematic reviews consistently show that vaginal estradiol significantly improves:

• Vaginal dryness and itching
• Painful sexual intercourse
• Urinary urgency and urinary incontinence
• Recurrent urinary tract infections

A review published in Obstetrics and Gynecology found that low-dose vaginal estrogen products improved both vaginal and urinary symptoms while maintaining systemic estradiol levels within the postmenopausal range.

For women suffering from recurrent UTIs — often dismissed as unrelated to menopause — vaginal estradiol addresses the root cause: the atrophy of urogenital tissues that makes those infections more likely and harder to clear.

The Medicare study makes this gap especially stark. Among women with recurrent UTIs, only 10.1% filled a vaginal estrogen prescription — and this group was the least likely of any GSM symptom category to receive one. Women with obvious vulvovaginal symptoms had more than a 14% fill rate; women with recurrent UTIs had less than half that likelihood of receiving a prescription. Vaginal estradiol is evidence-based for urinary symptoms. The women who needed it most for that specific problem were the least likely to be offered it.

Is Vaginal Estradiol Safe?

Yes — and the evidence on this is unusually strong.

Multiple large studies, including the Women's Health Initiative observational study and the Nurses' Health Study, found no link between vaginal estrogen and major health risks including cardiovascular disease, stroke, or breast cancer.

The evidence is especially clear for women with a history of breast cancer. A 2023 study published in Obstetrics and Gynecology found no increased risk of breast cancer recurrence in women with a prior breast cancer diagnosis who used vaginal estrogen for GSM. Oncologists and hormone specialists who work with breast cancer survivors increasingly support the use of vaginal estradiol for these women — the benefit to quality of life is real, and the risk profile is extremely low.

The reason the safety evidence is so strong is the mechanism: local application, minimal absorption, local effect. Vaginal estradiol is not systemic hormone therapy. It is a locally acting treatment for a locally caused problem.

If you're a woman past menopause: Vaginal symptoms are not inevitable, and they're not something you have to accept as permanent. The Menopause Solution is my 7-step course covering the full landscape of hormone optimization — including vaginal estradiol, what to ask your provider, and how to advocate for yourself when your doctor doesn't bring it up.

Start Step 1 Free →

What to Do If Your Doctor Isn't Helping

If you're dealing with vaginal dryness, painful sex, recurrent UTIs, or urinary urgency, and your provider hasn't mentioned vaginal estradiol, you have options.

Ask directly by name. "I'd like to discuss vaginal estradiol for genitourinary syndrome of menopause." Using the clinical term GSM signals that you know what you're talking about and makes it harder to be brushed off.

Know that the FDA warning concern is resolved. If your doctor cites the black box warning as a reason for hesitation, the FDA removed those warnings from HRT products including vaginal estrogen in November 2025. The concern about cardiovascular disease, breast cancer, and dementia was never supported by evidence for vaginal products — and the FDA has now acknowledged that formally.

Seek a hormone optimization specialist if needed. Not every primary care provider is equipped to navigate this. A provider with specific experience in hormone optimization for menopause is the right person to have this conversation with. I maintain a referral list of trained, experienced hormone optimization specialists — you can request a referral at simplehormones.com/referral.

Vaginal dryness treatment is not a luxury. It's not vanity. For many women, it's the difference between an intimate life and none, between chronic pain and relief, between suffering silently and finally feeling like themselves again.

The Bigger Picture

The 9% statistic is the one I keep coming back to. More than 1.8 million women with a diagnosed vaginal condition — and 91% without treatment. Not because the treatment doesn't exist. Not because it doesn't work. Not because it isn't safe.

Because of fear built on a warning that wasn't even based on the right product. And because of doctors who weren't trained to offer it.

Both of those barriers are now lower than they've ever been. The FDA has removed the warning. The evidence has never been stronger. The conversation is finally happening in the menopause community.

The question is whether it reaches your doctor's office — or whether you bring it there yourself.

A Note on This Post

I'm a pharmacist, not a physician. Nothing in this post is personal medical advice. This is educational content intended to help you have more informed conversations with your healthcare provider. Individual responses to vaginal estradiol vary, and factors including your health history, other medications, and specific symptoms should inform what form and dose are right for you. Work with a knowledgeable provider to find the approach that fits.